DDInter1544 DDInter1897
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity. Ulipristal is currently recommended as first line therapy for emergency contraception, due to improved efficacy and similar side effect profile as compared to the traditional use of levonorgestrel or the Yuzpe regimen. The exact mechanism of action for ulipristal is still currently debated, though there is evidence that it functions by inhibiting ovulation. A recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily debated due to ethical concerns related to abortion (Rosato et al, 2016). Nevertheless, current and ongoing research into the agent's mechanism of action as an emergency contraceptive continue to provide potentially plausible evidence that ulipristal may, in fact, elicit activity on the endometrium that prevents embryo implantation [A175372, A175375, A175378].
Ulipristal {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Ulipristal {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluconazole
Ulipristal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rivaroxaban
Ulipristal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Ulipristal {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Fluconazole
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Ulipristal may lead to a major life threatening interaction when taken with Edoxaban